Amgen/AMGN

$268.93

2.35%
-
1D1W1MYTD1YMAX

About Amgen

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.

Ticker

AMGN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Robert Bradway

Employees

26,700

Headquarters

Thousand oaks, United States

Amgen Metrics

BasicAdvanced
$141.52B
Market cap
21.14
P/E ratio
$12.49
EPS
0.61
Beta
$8.52
Dividend rate
3.41%
Dividend yield
$141.52B
0.61058
$329.72
$211.71
2.92M
$8.52
1.649
1.132
1,013.639
1,036.794
69.14%
38.123
3.15%
8.28%
135.79%
10.48%
21.143
5.02
22.687
50.489
2.85%
3.23%
3.41%
7.09%
3.07%
3.5%
0.47%
10.01%

What the Analysts think about Amgen

Analyst Ratings

Majority rating from 31 analysts.
Buy

Price Targets

Average projection from 23 analysts.
13.86% upside
High $380.00
Low $170.00
$268.93
Current price
$306.20
Average price target

Amgen Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
9.35% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$8.2B
18.73%
Net income
$767M
-55.66%
Profit margin
9.35%
-62.69%

Amgen Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 2.27%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$3.98
$5.00
$4.96
$4.71
-
Expected
$3.85
$4.49
$4.67
$4.61
$3.88
Surprise
3.45%
11.3%
6.16%
2.27%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Amgen stock?

Amgen (AMGN) has a market cap of $140.81B as of April 21, 2024.

What is the P/E ratio for Amgen stock?

The price to earnings (P/E) ratio for Amgen (AMGN) stock is 21.04 as of April 21, 2024.

Does Amgen stock pay dividends?

Yes, the Amgen (AMGN) stock pays dividends to shareholders. As of April 21, 2024, the dividend rate is $8.52 and the yield is 3.43%. Amgen has a payout ratio of 69.14% on a trailing twelve-month basis.

When is the next Amgen dividend payment date?

The next Amgen (AMGN) dividend payment is scheduled for June 07, 2024.

What is the beta indicator for Amgen?

Amgen (AMGN) has a beta rating of 0.61. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Amgen stock price target?

The target price for Amgen (AMGN) stock is $306.2, which is 13.86% above the current price of $268.93. This is an average based on projections from 23 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Amgen stock

Buy or sell Amgen stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing